Lexicon Pharmaceuticals, Inc. reports developments as a Nasdaq-listed biopharmaceutical company focused on the discovery, development and commercialization of medicines for human disease. Company news commonly covers pipeline updates in neuropathic pain, hypertrophic cardiomyopathy, obesity, metabolic disorders and other cardiometabolic indications, including clinical data presentations for sotagliflozin and pilavapadin.
Recurring updates also include operating and financial results, regulatory interactions, material agreements, financing arrangements and governance or shareholder-voting matters. Coverage of LXRX often connects capital-structure actions with the resources used to advance clinical and preclinical drug candidates.
Lexicon Pharmaceuticals (Nasdaq: LXRX) will present at three investor conferences in New York: Citi 2026 Biopharma Back to School Conference on September 9, 2026; 2026 Cantor Global Healthcare Conference on September 10, 2026; and H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026.
According to Lexicon Pharmaceuticals, live webcasts and replays of the presentations will be available via the Events page on its investor relations website.
Lexicon (Nasdaq: LXRX) reported a new post hoc analysis from the Phase 3 SOLOIST‑WHF trial, presented at ESC Congress 2026 and published in JACC: Heart Failure, evaluating sotagliflozin across baseline systolic blood pressure (SBP) in 1,222 patients with type 2 diabetes recently hospitalized for worsening heart failure.
According to Lexicon, sotagliflozin’s treatment effect on total cardiovascular deaths and heart failure-related events was consistent across SBP ranges, including patients with SBP as low as 100 mmHg, without increased hypotension or acute kidney injury. In SBP <110 mmHg (n=201), the hazard ratio was 0.56 (95% CI 0.33–0.95; p=0.03); in SBP ≥110 mmHg (n=1175), the hazard ratio was 0.69 (95% CI 0.53–0.91; p=0.01).
Lexicon Pharmaceuticals (Nasdaq: LXRX) reported earning a third $10 million milestone payment in 2026 from Novo Nordisk, triggered by a key patient dosing milestone in the ongoing Phase 1 clinical program for LX9851, an oral small molecule ACSL5 inhibitor for obesity and related metabolic disorders.
According to Lexicon, LX9851 is being developed by Novo Nordisk under an exclusive worldwide license agreement signed in 2025, under which Lexicon is eligible for up to $1 billion in upfront and milestone payments. With this event, Lexicon has received $75 million to date and is also entitled to tiered royalties on any future net sales. The Phase 1 trial, initiated in March 2026 in overweight or obese adults, evaluates safety, tolerability, pharmacokinetics and pharmacodynamics and is expected to complete in the first quarter of 2027. Preclinical data presented in 2024 showed enhanced weight and fat mass reductions when LX9851 was combined with semaglutide.
Lexicon Pharmaceuticals (Nasdaq:LXRX) reported second quarter 2026 revenues of $0.7 million, down from $28.9 million a year earlier, reflecting the absence of prior-period Novo Nordisk licensing revenue. The company posted a net loss of $31.8 million, or $0.07 per share, versus net income of $3.3 million, or $0.01 per share, in 2025.
R&D expenses rose to $17.4 million and SG&A to $9.8 million. Cash and investments increased to $190.6 million, aided by $96.2 million of February equity proceeds and a new $100 million Hercules Capital loan facility, of which $55 million was drawn to refinance prior debt.
Lexicon completed enrollment of the >500-patient Phase 3 SONATA-HCM study of sotagliflozin, with topline data expected in Q1 2027, and plans an NDA resubmission for ZYNQUISTA in type 1 diabetes in Q4 2026. Novo Nordisk’s Phase 1 obesity program for LX9851 is ongoing, with Lexicon eligible for up to $1 billion in milestones plus royalties.
Lexicon Pharmaceuticals (Nasdaq: LXRX) will release its second quarter 2026 financial results on Thursday, August 6, 2026, prior to market open. Management will host a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) to review results and provide a business update.
According to Lexicon, investors can access the live webcast via the Events page of its investor website, with separate registration required to receive dial-in details for asking questions. An archived webcast will be available. Lexicon is a biopharmaceutical company with drug candidates in neuropathic pain, hypertrophic cardiomyopathy, obesity, metabolic disorders, and other cardiometabolic indications.
Lexicon Pharmaceuticals (Nasdaq: LXRX) announced completion of patient randomization in the pivotal Phase 3 SONATA-HCM trial of sotagliflozin in symptomatic non-obstructive (nHCM) and obstructive (oHCM) hypertrophic cardiomyopathy. The study substantially exceeded its enrollment target of 500 patients across more than 130 sites in 20 countries.
The final population includes a substantial majority of nHCM patients and a meaningful oHCM cohort. The randomized, double-blind, placebo-controlled trial evaluates symptoms, function, patient-reported outcomes and safety, with the primary endpoint being change from baseline to week 26 in KCCQ Clinical Summary Score. Topline results are anticipated in Q1 2027.
Lexicon (Nasdaq:LXRX) will present new clinical data at the American Diabetes Association (ADA) 2026 Scientific Sessions, June 5-8 in New Orleans.
Posters will cover sotagliflozin in type 1 diabetes, highlighting consistent A1c reductions, and pilavapadin pharmacokinetics across renal function groups.
Lexicon Pharmaceuticals (Nasdaq:LXRX) announced that company management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 4, 2026, at 2:00 p.m. ET in New York City.
The live event and replay will be available via the Events page of Lexicon's investor website.
Lexicon Pharmaceuticals (Nasdaq:LXRX) announced that management will take part in a fireside chat at the 4th Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq World Headquarters in New York City on May 19, 2026. A live webcast and replay will be available on the company’s investor relations Events page.
Lexicon Pharmaceuticals (Nasdaq: LXRX) reported Q1 2026 results and pipeline updates on May 7, 2026. Key points: Total revenue $21.1M (including a $20.0M Novo Nordisk milestone), cash, investments and restricted cash $199.7M, and a $100M Hercules loan facility with $55M funded.
Clinical highlights: SONATA-HCM enrollment expected mid-2026, potential NDA resubmission for ZYNQUISTA mid-2026, and Novo Nordisk initiated Phase 1 for LX9851.